Lv61
2070 积分 2024-07-23 加入
Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial
1小时前
已完结
Inflammatory Myopathies
1小时前
已完结
Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series
29天前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
1个月前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
1个月前
已完结
T-cell engagers in rheumatology
1个月前
已完结
The present and future of bispecific antibodies for cancer therapy
1个月前
已完结
Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases
1个月前
已完结
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis
1个月前
已完结
皖公网安备34019202002308
